Are antibiotic doses right for High-Risk surgery patients?

NCT ID NCT07558681

Not yet recruiting Knowledge-focused Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the usual dose of the antibiotic piperacillin/tazobactam is enough to prevent infections during major liver or pancreas surgery. Researchers will measure antibiotic levels in the blood of 60 adult patients during surgery. The goal is to see if current dosing works or needs to be adjusted for these high-risk procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: piperacillin/tazobactam (antibiotic)
What this could lead to: If successful, this could lead to better antibiotic dosing guidelines for liver and pancreas surgery patients, potentially reducing surgical infections.
What could go wrong: This is a small, early observational study (60 people) that only measures drug levels—it does not test whether infections are actually prevented. Results may not apply to all hospitals or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIBIOTIC PROPHYLAXIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Surgical Wound Infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIBIOTIC PROPHYLAXIS HEPATIC SURGERY PANCREATIC SURGEY

Contacts and locations

Locations

CHRU de Nancy

Vandœuvre-lès-Nancy, Lorraine, 54500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.